IMPROVING THE EFFICIENCY OF DRUG BY INCORPORATING IN POLYMERIZED LIPID NANOPARTICLE FOR RHEUMATOID ARTHRITIS

Mancy S. P., Dr. Hemalatha K. P.*, Dr. Manjunath K., Dr. Sachin Kumar Singh, Dr. Gaurav Gupta, Sukriti Vishwas and Dr. Vijay Kumar S.

ABSTRACT

Rheumatoid arthritis (RA) is the most common type of autoimmune arthritis. It is characterized by joint cellular infiltration and synovial inflammation, which progresses to joint degeneration and bone erosion. Immune dysfunction, cartilage and joint degradation are side effects of RA. It is also associated with several comorbidities like rheumatoid nodules, pulmonary disease, and can have a negative effect on one's overall health. Early therapies for RA can stop joint degeneration and deformities while also reducing symptoms. In addition, it will also result in better long-term outcomes and to avoid joint replacement surgery. Conventional, small-molecule, and biological antirheumatic drugs are used in current RA therapy. However, the present treatments have several limitations like poor absorption, safety and rapid metabolisms adverse effects like systemic toxicity, dose-escalation, lack of selectivity. Intensive research and development in the field of drug development and nano-technologies have led to improvised treatment approaches in RA. Treatment via novel drug delivery systems is being investigated thoroughly in the present era. Nanotechnology offers many benefits in treating several chronic diseases by delivering the drugs to target sites. An updated list of currently approved treatments and cutting-edge drug delivery technologies are presented in this review for the treatment of RA. In addition, we have compiled data from several studies which utilize NPs as a drug delivery system with good outcomes.

Keywords: Disease-modifying antirheumatic drug, Rheumatoid arthritis, Nanoparticles, Solid lipid nanoparticles, Autoimmune disease, Quality of Life.